Vasculitis: Determinants of disease patterns

Nature Reviews Rheumatology

Volumn 10, Issue 8, 2014, Pages 454-462

  Hoffman, Gary S ^a   Calabrese, Leonard H ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CXCL13 CHEMOKINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; TOLL LIKE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

AGING; ANGIOGENESIS; AUTOIMMUNITY; BLOOD VESSEL DIAMETER; BLOOD VESSEL FUNCTION; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; DISEASE CLASSIFICATION; DISEASE COURSE; EMBRYO DEVELOPMENT; GOODPASTURE SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOPATHOGENESIS; INFECTION; KIDNEY; MICROVASCULARIZATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; SKIN; THROMBOCYTE AGGREGATION; VASCULITIS; AUTOIMMUNE DISEASE; BLOOD VESSEL; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; PATHOLOGY; SKIN BLOOD VESSEL DISORDER; SYSTEMIC VASCULITIS;

AUTOIMMUNE DISEASES; BLOOD VESSELS; DIAGNOSIS, DIFFERENTIAL; HUMANS; SKIN DISEASES, VASCULAR; SYSTEMIC VASCULITIS; VASCULITIS;

EID: 84905502363     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.89     Document Type: Review

References (75)

1. Rocha, S. F. & Adams, R. H. Molecular differentiation and specialization of vascular beds. Angiogenesis 12, 139-147 (2009).
2. Cleaver, O. & Melton, D. A. Endothelial signaling during development. Nat. Med. 9, 661-668 (2003).
3. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932-936 (2005).
4. Swift, M. R. & Weinstein, B. M. Arterial-venous specification during development. Circ. Res. 104, 576-588 (2009).
5. Larrivée, B., Freitas, C., Suchting, S., Brunet, I. & Eichmann, A. Guidance of vascular development: lessons from the nervous system. Circ. Res. 104, 428-441 (2009).
6. Ribatti, D., Nico, B. & Crivellato, E. Morphological and molecular aspects of physiological vascular morphogenesis. Angiogenesis 12, 101-111 (2009).
7. Davis, G. E. & Senger, D. R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 97, 1093-1107 (2005).
8. Hallmann, R. et al. Expression and function of laminins in the embryonic and mature vasculature. Physiology Rev. 85, 979-1000 (2005).
9. Stan, R. V. Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis. J. Cell. Mol. Med. 11, 621-643 (2007).
10. Pries, A. R. & Kuebler, W. M. Normal endothelium. Handbook Exptl Pharmacol. 176, 1-40 (2006).
11. Sá-Pereira, I., Brites, D. & Brito, M. A. Neurovascular unit: a focus on pericytes. Mol. Neurobiol. 45, 327-347 (2012).
12. Molema, G. & Aird, W. C. Vascular heterogeneity in the kidney. Semin. Nephrol. 32, 145-155 (2012).
13. Okuyama, K., Yaginuma, G., Takahashi, T., Sasaki, H. & Mori, S. The development of vasa vasorum of the human aorta in various conditions. A morphometric study. Arch. Pathol. Lab. Med. 112, 721-725 (1988).
14. Margolin, D. A. et al. Differential monocytic cell adherence to specific anatomic regions of the canine aorta. J. Vasc. Res. 32, 266-274 (1995).
15. Topouzis, S. & Majesky, M. W. Smooth muscle lineage diversity in the chick embryo: two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-β. Dev. Biol. 178, 430-445 (1996).
16. Majesky, M. W. Developmental basis of vascular smooth muscle diversity. Arterioscler. Thromb. Vasc. Biol. 27, 1248-1258 (2007).
17. Pryshchep, O., Ma-Krupa, W., Younge, B. R., Goronzy, J. J. & Weyand, C. M. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118, 1276-1284 (2008).
18. Foster, T. J., Geoghegan, J. A., Ganesh, V. K. & Höök, M. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat. Rev. Microbiol. 12, 49-62 (2014).
19. Vengadesan, K. & Narayana, V. L. Structural biology of Gram-positive bacterial adhesins. Protein Sci. 20, 759-772 (2011).
20. Belouzard, S., Millet, J. K., Licitra, B. N. & Whittaker, G. R. Mechanisms of Coronavirus cell entry mediated by the viral spike protein. Viruses 4, 1011-1033 (2012).
21. Cuperus, T., Coorens M, van Dijk, A. & Haagsman, H. P. Avian host defense peptides. Dev. Comp. Immunol. 41, 352-369 (2013).
22. Zhao, L. & Lu, W. Defensins in innate immunity. Curr. Opin. Hematol. 21, 37-42 (2014).
23. Guillevin, L. Infections in vasculitis. Best Pract. Res. Clin. Rheumatol. 27, 19-31 (2013).
24. Calabrese, L. H. Infection with the human immunodeficiency virus type 1 and vascular inflammatory disease. Clin. Exp. Rheumatol. 22 (Suppl. 36), S87-S93 (2004).
25. Weck, K. E. et al. Murine γ-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-γ responsiveness: a new model for virus-induced vascular disease. Nat. Med. 3, 1346-1353 (1997).
26. Presti, R. M., Pollock, J. L., Dal Canto, A. J., O'Guin, A. K. & Virgin, H. W. Interferon γ regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J. Exp. Med. 188, 577-588 (1998).
27. Dal Canto, A. J., Swanson, P. E., O'Guin, A. K., Speck, S. H. & Virgin, H. W. IFN-γ action in the media of the great elastic arteries, a novel immunoprivileged site. J. Clin. Invest. 107, R15-R22 (2001).
28. Agnello, V., Chung, R. T. & Kaplan, L. M. A role for hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med. 327, 1490-1495 (1992).
29. Antonelli, A. et al. Serum concentrations of interleukin 1β, CXCL10, and interferon-γ in mixed cryoglobulinemia associated with hepatitis C infection. J. Rheumatol. 37, 91-97 (2013).
30. Sansonno, D. & Dammacco, F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect. Dis. 5, 227-236 (2005).
31. Fabrizi, F. et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am. J. Kidney Dis. 61, 623-637 (2013).
32. Cacoub, P., Terrier, B. & Saadoun, D. Hepatitis C virus-induced vasculitis: therapeutic options. Ann. Rheum. Dis. 73, 24-30 (2014).
33. Ferri, C. et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig. Liver Dis. 39 (Suppl. 1), S13-S21 (2007).
34. Saadoun, D. et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res. (Hoboken) 63, 427-435 (2011).
35. Zeisel, M. B., Felmlee, D. J. & Baumert, T. F. Hepatitis C viral entry. Curr. Topics Microbiol. Immunol. 369, 86-112 (2013).
36. Catanese, M. T. et al. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J. Virol. 87, 8282-8293 (2013).
37. Ferri, C., Zignego, A. L. & Pileri, S. A. Cryoglobulins. J. Clin. Pathol. 55, 4-13 (2002).
38. Alpers, C. E. & Smith, K. D. Cryoglobulinemia and renal disease. Curr. Opin. Nephrol. Hypertens. 17, 243-249 (2008).
39. Gorevic, P. D. Rheumatoid factor, complement, and mixed cryoglobulinemia. Clin. Dev. Immunol. 2012, 439018 (2012).
40. Sansonno, D. et al. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. Blood 112, 1620-1627 (2008).
41. Sansonno, D. B. et al. Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J. Immunol. 183, 6013-6020 (2009).
42. Dammacco, F. & Sansonno, D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N. Engl. J. Med. 369, 1035-1045 (2013).
43. Fabrizi, F. et al. Biological dynamics of hepatitis B virus load in dialysis population. Am. J. Kidney Dis. 41, 1278-1285 (2003).
44. Fornasieri, A. & D'Amico, G. Type II mixed cryoglobulinaemia, hepatitis C virus infection, and glomerulonephritis. Nephrol. Dial. Transplant. 11 (Suppl. 4), 25-30 (1996).
45. Cacoub, P. et al. Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. J. Hepatol. 31, 598-603 (1999).
46. Barsoum, R. S. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol. Dial. Transplant. 22, 1840-1848 (2007).
47. Sansonno, D. et al. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin. Exp. Immunol. 140, 498-506 (2005).
48. Saadoun, D. et al. Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum. 52, 2917-2925 (2005).
49. Wornle, M. et al. Novel role of Toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am. J. Pathol. 168, 370-385 (2006).
50. Authier, F. J. et al. Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy. Neurology 60, 808-812 (2003).
51. Fletcher, N. F. et al. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 142, 634-643 (2012).
52. Forton, D. M., Karayiannis, P., Mahmud, N., Taylor-Robinson, S. D. & Thomas, H. C. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J. Virol. 78, 5170-5183 (2004).
53. Sabahi, A. Hepatitis C virus entry: the early steps in the viral replication cycle. Virol. J. 6, 117 (2009).
54. Feray, C. Is HCV infection a neurologic disorder? Gastroenterology 142, 428-431 (2012).
55. Burlone, M. E. & Budkowska, A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol. 90, 1055-1070 (2009).
56. Wilkinson, J., Radkowski, M. & Laskus, T. Hepatitis C virus neuroinvasion: identification of infected cells. J. Virol. 83, 1312-1319 (2009).
57. Fletcher, N. F. et al. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology 59, 1320-1330 (2014).
58. Jia, X. Y., Cui, Z., Yang, R., Hu, S. Y. & Zhao, M. H. Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury. Clin. J. Am. Soc. Nephrol. 7, 926-933 (2012).
59. Vanacore, R., Pedchenko, V., Bhave, G. & Hudson, B. G. Sulphilimine cross-links in Goodpasture's disease. Clin. Exp. Immunol. 164, 4-6 (2011).
60. Peto, P. & Salama, A. D. Update on antiglomerular basement membrane disease. Curr. Opin. Rheumatol. 23, 32-37 (2011).
61. Ooi, J. D. et al. The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN. J. Am. Soc. Nephrol. 24, 419-431 (2013).
62. Doyle, H. A. & Mamula, M. J. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr. Opin. Immunol. 24, 112-118 (2012).
63. Hernández-Rodriguez, J. et al. Vasculitis involving the breast: a clinical and histological analysis of 34 patients. Medicine (Baltimore) 87, 61-69 (2008).
64. Hernández-Rodríguez, J., Tan, C. D., Rodríguez, R. E. & Hoffman, G. S. Gynecologic vasculitis: an analysis of 163 patients. Medicine (Baltimore) 88, 169-181 (2009).
65. Hernández-Rodríguez, J. & Hoffman, G. S. Updating single-organ vasculitis. Curr. Opin. Rheumatol. 24, 38-45 (2012).
66. Jennette, J. C. et al. Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 65, 1-11 (2013).
67. Falk, R. J. & Hoffman, G. S. Controversies in small vessel vasculitis-comparing rheumatology and nephrology views. Curr. Opin. Rheumatol. 19, 1-9 (2007).
68. Sablé-Fourtassou, R. et al. Antineutrophil cytoplasm antibodies and the Churg-Strauss syndrome. Ann. Intern. Med. 143, 632-638 (2005).
69. Sinico, R. A. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 52, 2926-2935 (2005).
70. Ribatti, D., Nico, B., Vacca, A., Roncali, L. & Dammacco, F. Endothelial cell heterogeneity and organ specificity. J. Hematother. Stem Cell Res. 11, 81-90 (2002).
71. Mohan, S., Liao, Y., Kim, J., Goronzy, J. & Weyand, C. Giant cell arteritis: immune and vascular aging as disease risk factors. Arthritis Res. Ther. 13, 231 (2011).
72. Maksimowicz-McKinnon, K., Clark, T. M. & Hoffman, G. S. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore) 88, 221-226 (2009).
73. Grayson, P. C. et al. Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann. Rheum. Dis. 71, 1329-1334 (2012).
74. Zivkovic, S. A., Clemens, P. R. & Lacomis, D. Characteristics of late-onset myasthenia gravis. J. Neurol. 259, 2167-2171 (2012).
75. Aarli, J. A. Myasthenia gravis in the elderly: is it different? Ann. N. Y. Acad. Sci. 1132, 238-243 (2008).